LEADER 02406oas  2201045 a 450 
001 9910154537303321
005 20260203110340.0
011   $a1532-4192
035   $a(DE-599)ZDB2043112-0
035   $a(OCoLC)48483445
035   $a(CONSER)  2006268256
035   $a(CKB)954925536095
035   $a(DE-599)2043112-0
035   $a(EXLCZ)99954925536095
100   $a20011126a19839999  sy         a
101 0 $aeng
135   $aurmnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCancer investigation
210   $a[New York, NY] $cMarcel Dekker
300   $aRefereed/Peer-reviewed
300   $aPublished: Abingdon, Oxfordshire : Taylor & Francis, <2006->
311 08$a0735-7907 
531 0 $aCancer investig.
606   $aCancer$vPeriodicals
606   $aOncology$vPeriodicals
606   $aMedical Oncology
606   $aNeoplasms
606   $aCancer$vPe?riodiques
606   $aCance?rologie$vPe?riodiques
606   $aOncology$2ebps
606   $aCancer$2fast$3(OCoLC)fst00845317
606   $aOncology$2fast$3(OCoLC)fst01045739
608   $aPeriodical.
608   $aPeriodicals.$2fast
608   $aPeriodicals.$2lcgft
615  0$aCancer
615  0$aOncology
615  2$aMedical Oncology.
615  2$aNeoplasms.
615  6$aCancer
615  6$aCance?rologie
615  7$aOncology.
615  7$aCancer.
615  7$aOncology.
676   $a616.994
801  0$bF#A
801  1$bF#A
801  2$bOCLCQ
801  2$bMXC
801  2$bOCLCQ
801  2$bMXC
801  2$bMUQ
801  2$bGUA
801  2$bUKMGB
801  2$bOCLCQ
801  2$bDLC
801  2$bOCLCF
801  2$bOCLCO
801  2$bVT2
801  2$bHUA
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCQ
801  2$bWT2
801  2$bUEJ
801  2$bOCLCQ
801  2$bNLE
801  2$bOCLCQ
801  2$bOCLCO
801  2$bAU@
801  2$bOCLCO
801  2$bWYU
801  2$bAUD
801  2$bU3W
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCA
801  2$bSFB
801  2$bUBY
801  2$bOCLCO
801  2$bOCLCA
801  2$bOCLCQ
801  2$bOCLCL
906   $aJOURNAL
912   $a9910154537303321
996   $aCancer investigation$92024781
997   $aUNINA